Lee et al, 1 comprising authors from a number of institutions, published a retrospective observational study conducted on 147 consecutive patients who underwent endoscopic enucleation of the prostate ...

At the 2026 UCSF-UCLA PSMA Conference, Lisa Bodei reviews PSMA response biomarkers for lutetium PSMA therapy. She presents data from the TheraP and VISION trials showing that baseline SUV mean, ...

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Alicia Morgans discussing the incorporation of PSMA PETs in registrational trials. To ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Ruth Langley discussing efficacy results from a randomized phase 3 evaluation of ...

ASCO GU 2024 Press Releases Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024 Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% ...

Tumor suppressor genes play a critical role in prostate cancer progression, with alterations in PTEN, TP53, and RB1 representing some of the most clinically significant genomic events. These ...

AUA 2025 Upper Tract Urothelial Carcinoma AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma AUA 2025: Long-Term ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Yi-Jun Shen discussing HERO, a ...